Sun Pharmaceutical (SUNPHARMA) Share Price & Analysis
Sun Pharmaceutical (SUNPHARMA) — Drug Manufacturers - Specialty & Generic
Sun Pharmaceutical Key Fundamental Metrics
Executive Investment Overview & Business Profile
Sun Pharmaceutical commands a premium valuation with a P/E of 38.664288, supported by high market dominance and profitability expectations.
Sun Pharmaceutical is one of the premier companies in India's Healthcare sector. Currently trading at ₹1,951 with a market capitalization of ₹4.68 Lakh Cr, the company occupies a key position in the Indian equity market.
Investors evaluating Sun Pharmaceutical focus closely on its capital return metrics: Return on Equity (ROE) stands at N/A alongside operating margins of 23.25%. The company's earnings multiple of 38.664288 P/E provides a clear signal of market expectation relative to sector peers.
Company Profile & Information
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; specialty medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers generics and APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. Sun Pharmaceutical Industries Limited was founded in 1983 and is headquartered in Mumbai, India.